Breaking Finance News

Bankhaus Lampe KG disclosed EVOTEC (ETR:EVT), hiking its price target to 5.40EUR earlier today

Having a price of 5.10EUR, EVOTEC (ETR:EVT) traded -0.99% lower on the day. With the last close down -0.95% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. EVT has recorded a 50-day average of 20.58EUR and a two hundred day average of 20.22EUR. Trade Volume was down over the average, with 127,115 shares of EVT changing hands under the typical 129,295

Reporting a potential upside of 0.06%, Bankhaus Lampe KG upped the price target of EVOTEC (ETR:EVT) to 5.40EUR

On Tuesday October 04, 2016, Bankhaus Lampe KG released a statement on EVOTEC (ETR:EVT) upped the target price from 0.00EUR to 5.40EUR that suggested an upside of 0.06%.

Recent Performance Chart


EVOTEC has 52 week low of 16.37EUR and a 52 week high of 21.25EUR and has a market cap of 0 EUR.

General Information About EVOTEC (ETR:EVT)

Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator's targets and programs. EVT Innovate focuses on developing its internal assets, including early-stage discovery programs, as well as drug candidates. The Company focuses on therapeutic areas, including central nervous system (CNS)/neurology, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. Its clinical products include EVT302, EVT201, EVT100 and EVT401. Its pre-clinical products include EVT770, EVT801, EVT701 and EVT601. EVT302 is an inhibitor of monoamine oxidase type B (MAO-B), an enzyme that breaks down the chemical messenger dopamine in the brain and contributes to the production of free radicals.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.